Basic information Safety Supplier Related

L-689,560

Basic information Safety Supplier Related

L-689,560 Basic information

Product Name:
L-689,560
Synonyms:
  • L-689,560
  • TRANS-2-CARBOXY-5,7-DICHLORO-4-PHENYLAMINOCARBONYLAMINO-1,2,3,4-TETRAHYDROQUINOLINE
  • 4-trans-2-carboxy-5,7-dichloro-4-phenylaminocarbonylamino-1,2,3,4-tetrahydroquinoline
  • 2-Quinolinecarboxylic acid, 5,7-dichloro-1,2,3,4-tetrahydro-4-[[(phenylamino)carbonyl]amino]-, (2R,4S)-rel-
CAS:
139051-78-8
MF:
C17H15Cl2N3O3
MW:
380.23
Mol File:
139051-78-8.mol
More
Less

L-689,560 Chemical Properties

Melting point:
172-173°C
Boiling point:
549.1±50.0 °C(Predicted)
Density 
1.51±0.1 g/cm3(Predicted)
storage temp. 
Store at RT
solubility 
<9.51mg/ml in DMSO; <38.02mg/ml in ethanol
form 
solid
pka
11.16±0.20(Predicted)
color 
White
More
Less

L-689,560 Usage And Synthesis

Uses

L-689,560 is a potent antagonist at the glycine-NMDA receptor site.

Definition

ChEBI: 4-[[anilino(oxo)methyl]amino]-5,7-dichloro-1,2,3,4-tetrahydroquinoline-2-carboxylic acid is a member of quinolines.

Biological Activity

Very potent antagonist at the glycine-NMDA site. Also available as part of the NMDA Receptor - Glycine Site Tocriset™ .

in vitro

l-689560 is described as one of the most potent nmda antagonists and [4'-3h]-l-689560 has been thought to be a highly specific radioligand for the glycine site. in consistent with the 5,7-disubstituted kynurenates, the tetrahydroquinolines are selective antagonists of glycine site nmda, l-689560 exhibiting at least 3 orders of magnitude selectivity versus the glutamate site [1].

in vivo

mdl100748 with an ed50 of 83 mg kg-1 can prevent audiogenic seizures in susceptible mice after systemic injection. as a standard l689560, its subsequent analogues have been compared; the displacement of [3h] l689560 has often been used to displace that of [3h] glycine as an alternative assay. l701252, a quinones (the retention of a keto grouping at position 3), has been against l689560 binding (ic50 of 420 nm) and against seizures (ed50 of 4.1 mg kg-1) in dba/2 mice. a group of sulfonamide analogues of kynurenic acid are also in active among the 2-quinolone series. those of a series of 3,4-dihydroquinolones and tetrahydroquinolines with a nitrosubstituent at 3-position were selective antagonists at the nmda receptor glycine site if they bore a bulky grouping in the position 4. the compound with no substitution at position 4 was proved to be one of the most effective broad-spectrum antagonists against nmda and ampa receptors [2].

storage

Store at RT

References

[1]. leeson pd, carling rw, moore kw, moseley am, smith jd, stevenson g, chan t, baker r, foster ac, grimwood s, et al. 4-amido-2-carboxytetrahydroquinolines. structure-activity relationships for antagonism at the glycine site of the nmda receptor. j med chem. 1992 may 29;35 (11): 1954-68.
[2]. stone tw. development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection. trends pharmacol sci. 2000 apr; 21(4):149-54.

L-689,560Supplier

Meryer (Shanghai) Chemical Technology Co., Ltd.
Tel
021-61259108 18621169109
Email
market03@meryer.com
3B Pharmachem (Wuhan) International Co.,Ltd.
Tel
821-50328103-801 18930552037
Email
3bsc@sina.com
EMMX Biotechnology LLC
Tel
888-539-0666
Email
info@emmx.com
Aikon International Limited
Tel
025-66028182 18112977050
Email
cfzhang@aikonchem.com
Jinan Yaoyan Pharmaceutical Co., Ltd.
Tel
Email
jnyaoyan@163.com